Structural and functional cardiac abnormalities during chronic kidney disease
Main Article Content
Keywords
Cardio-Renal Syndrome, Renal Insufficiency, Chronic, Cardiovascular Diseases, Drug Therapy
Abstract
Cardiovascular diseases are the leading cause of death in people with chronic kidney disease (CKD). These involve the whole structure and function of the heart, so the clinical presentation varies from chronic heart failure to arrhythmias and even sudden death, having a significant impact on the patient’s quality of life and a high cost for health services. The origin of these cardiovascular alterations is ample, involving the traditional and non-traditional cardiovascular risk factors, as well as systemic changes that cause the progressive loss of the glomerular filtration rate. The identification of cardiovascular alterations during the course of the CKD has become important in the clinical setting, and there is a wide field of research regarding treatment interventions, many of which have not been fully established up to date
References
Clementi A, Virzi GM, Brocca A, de Cal M, Vescovo G, Granata A et al. Cardiorenal síndrome type 4: Management. Blood Puriff. 2013;36:200-209.
Gigante A, Liberatori M, Ludovica-Gasperini M, Sardo L, Di Mario F, Dorelli B et al. Prevalence and clinical features of patients with the cardio renal syndrome admitted to an Internal Medicine Ward. Cardio renal Med. 2015;4(2):88-94.
Pavan M. Incidence of acute cardio renal syndrome type 3 in India. IJKD. 2014;8:42-5.
Iacovello M, Leone M, Antoncecchi V, Ciccone MM. Evaluation of chronic kidney disease in chronic heart failure: from biomarkers to arterial renal resistances. World Journal of Clin Cases. 2015;16(3):10-9.
Palomo-Piñón S, Mora-Villalpando CJ, Prado-Uribe MC, Ceballos-Reyes GM, Ventura García MJ, ÁvilaDíaz M et al. Inflammation and myocardial damage markers influence loss of residual renal function in peritoneal dialysis patients. Archives of Medical Research. 2014;45:484-488.
Prado-Uribe MC, Soto-Abraham MV, MoraVillalpando CJ, Gallardo JM, Bonilla E, Ávila M et al. Role of thyroid hormones and mir-208 in myocardial remodeling in 5/6 nephrectomized rats. Archives of Medical Research. 2013;44:616-622.
Mejía-Rodríguez O, Herrera-Abarca JE, CeballosReyes G, Ávila-Díaz M, Prado-Uribe C, BelioCaro F et al. Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease. BioMed Research International. 2013;2013:104059.
Clementi A, Virzi GM, Yan Goh C, Cruz DN, Granata A, Vescovo G et al. Cardiorenal síndrome type 4: A review. Cardio-renal Med. 2013;3:63-70.
Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: A statement for health professionals. Circulation. 1991;83:356-62.
Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24:987-1003.
Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease. A systematic integrative review. BioMed Research International. 2014:937398.
González-Juanatey JR, Cea-Calvo L, Bertomeu V, Aznar J. Criterios electrocardiográficos de hipertrofia ventricular izquierda y perfil de riesgo cardiovascular en hipertensos. Estudio VIIDA. Rev Esp Cardiol. 2007;60(2):148-56.
AY Wang, JE Sanderson. Current perspectives on diagnosis of heart failure in long-term dialysys patients. American Journal of Kidney Diseases. 2011;57(2):308-319.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C et al. Evidence basedguideline for the management of high blood pressure in adults: Report from de panel members appointed to the Eight Joint Nationalo Commitee (JNC8). JAMA. 2014. DOI:10.1001/Jama.2013.284427.
Zannad F, Kessker M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz, A et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70:1318-1324.
Palmer SC, Navaneetham SD, Craig JC, Johnson DW, Tonelli M, Grarg AX et al. Meta-analysis: erithropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23-33.
Wajeh Y, Qunibi C. Hyperphosphatemia. The CARE Study and cardiovascular calcification. Supplemento to Managed Care. 2006;15(3):1-8.
Mohamed ES, Stenvinkel P. Contribution of inflammation to vascular disease in chronic kidney disease patients. Saudi J Kidney Dis Transplant. 2008;19(3):329-345.
Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-82.
Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulindependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157:1413-8.
Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens. 1996;14:223-8.
Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension and diabetes. Circulation. 2004;110:32-5.
Jarraya F, Lakhdar R, Kaummoun K, Mahfoudh H, Drissa H, Kammoun S et al. Microalbuminuria: a useful marker of cardiovascular disease. IJKD. 2013;7:178-86.
Matthew RW. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2:581-590.
Amlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation. 2005;112:969-75